Literature DB >> 8740860

Fluconazole treatment of candidal infections caused by non-albicans Candida species.

J W van 't Wout1.   

Abstract

Fluconazole is an effective alternative to amphotericin B for the treatment of serious infections caused by Candida albicans. Through a literature survey of candidal infections caused by non-albicans Candida spp., 43 cases treated with fluconazole were found. The most common causative organisms were Candida parapsilosis (14 patients), Candida glabrata (12 patients), and Candida tropicalis (11 patients). The dose of fluconazole varied from 50 to 400 mg daily. The median duration of treatment was 21 days. Overall efficacy was 77%. The efficacy against the various species was 93% for Candida parapsilosis, 50% for Candida glabrata, and 82% for Candida tropicalis. In conclusion, fluconazole is effective against the most common non-albicans Candida spp., although higher doses may be required for infections caused by Candida glabrata. Infections caused by Candida krusei should not be treated with fluconazole.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740860     DOI: 10.1007/bf01591361

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  25 in total

1.  Fluconazole in the treatment of fungal infections in kidney-transplanted patients.

Authors:  A Bren; A Kandus; J Lindic; J Varl
Journal:  Transplant Proc       Date:  1992-12       Impact factor: 1.066

2.  Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhlitis.

Authors:  M A McIlroy
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

Review 3.  Fluconazole treatment of fungal infections in the immunocompromised host.

Authors:  F Meunier
Journal:  Semin Oncol       Date:  1990-06       Impact factor: 4.929

4.  Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.

Authors:  J H Rex; M A Pfaller; A L Barry; P W Nelson; C D Webb
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

5.  Treatment of Candida albicans fungaemia with fluconazole.

Authors:  W Graninger; E Presteril; B Schneeweiss; B Teleky; A Georgopoulos
Journal:  J Infect       Date:  1993-03       Impact factor: 6.072

6.  Efficacy of fluconazole in the treatment of systemic fungal infections.

Authors:  D Milatovic; A Voss
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

Review 7.  Importance of Candida species other than C. albicans as pathogens in oncology patients.

Authors:  J R Wingard
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

8.  Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy.

Authors:  E Anaissie; G P Bodey; H Kantarjian; C David; K Barnett; E Bow; R Defelice; N Downs; T File; G Karam
Journal:  Am J Med       Date:  1991-08       Impact factor: 4.965

9.  A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections.

Authors:  J W Van't Wout; H Mattie; R van Furth
Journal:  J Antimicrob Chemother       Date:  1988-05       Impact factor: 5.790

Review 10.  Fluconazole in the management of fungal ocular infections.

Authors:  S F Urbak; T Degn
Journal:  Ophthalmologica       Date:  1994       Impact factor: 3.250

View more
  8 in total

1.  Successful treatment of fungus balls due to fluconazole-resistant Candida sake obstructing ureter stents in a renal transplant patient.

Authors:  S M Arend; E J Kuijper; B J de Vaal; J W de Fijter; J W van't Wout
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

2.  When should Candida isolates be tested for susceptibility to azole antifungal agents?

Authors:  J Bille
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

3.  Characterization of agglutinin-like sequence genes from non-albicans Candida and phylogenetic analysis of the ALS family.

Authors:  L L Hoyer; R Fundyga; J E Hecht; J C Kapteyn; F M Klis; J Arnold
Journal:  Genetics       Date:  2001-04       Impact factor: 4.562

4.  Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Fluconazole Global Susceptibility Study Group.

Authors:  J Bille; M P Glauser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

5.  Secreted aspartic proteinase family of Candida tropicalis.

Authors:  C Zaugg; M Borg-Von Zepelin; U Reichard; D Sanglard; M Monod
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

6.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

7.  Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection.

Authors:  Jose A Vazquez
Journal:  HIV AIDS (Auckl)       Date:  2010-04-28

8.  Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.

Authors:  Jose A Vazquez
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.